Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation Study of STX-S as a Booster for SARS-CoV-2 Prevention
NCT07095231Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of STX-S in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of abnormal clinical safety laboratory adverse events, Occurrence of adverse events of special interest and 6 more. Started Aug 2025; status: completed.
02
Drugs
STX-S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07095231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095231.